|
Synonyms: ACD79B-VCMMAE | polatuzumab vedotin-piiq | Polivy® | RG-7596 | RG7596 | RO5541077-000
polatuzumab vedotin is an approved drug (FDA (2019), EMA (2020))
Compound class:
Antibody
Comment: Polatuzumab vedotin is an antibody drug conjugate containing an anti-CD79b monoclonal antibody linked to the toxin monomethyl auristatin E (MMAE, aka vedotin; PubChem CID 11542188).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence matches identify US8088378 as the claiming patent [1]. |
| References |
|
1. Chen Y, Dennis M, Dornan D, Elkins K, Junutula JR, Polson A, Zheng B. (2012)
Anti-CD79B antibodies and immunoconjugates and methods of use. Patent number: US8088378 B2. Assignee: Genetech Inc.. Priority date: 16/07/2007. Publication date: 03/01/2012. |
|
2. Deeks ED. (2019)
Polatuzumab Vedotin: First Global Approval. Drugs, 79 (13): 1467-1475. [PMID:31352604] |
|
3. Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, Slaga DS, Giere L, Du C, Tan C et al.. (2007)
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood, 110 (2): 616-23. [PMID:17374736] |
